Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

• DOI: 10.3389/fonc.2021.641955
• Publication Date: 2021-05-11T15:41:20Z
• Authors: Tianwang Guan; Zicong Qiu; Miao Su; Jinming Yang; Yongshi Tang; Yanting Jiang; Dunchen Yao; Yanxian Lai; Yanfang Li; Cheng Liu
• Keywords: cardio-oncology; primary central nervous system lymphoma; non-central nervous system lymphoma; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; chemotherapy; 16. Peace & justice; cardiovascular death; 3. Good health; SEER; 03 medical and health sciences; 0302 clinical medicine; Oncology; RC254-282

To study the cardiovascular death (CVD) risk in primary central nervous system lymphoma (PCNSL) patients with chemotherapy.We obtained 2,020 PCNSL participants and 88,613 non-central (NCNSL) chemotherapy from Surveillance, Epidemiology, End Results (SEER) database 2004 to 2015. A 1:3 propensity score matching (PSM) was used reduce imbalance between without chemotherapy, as well NCNSL chemotherapy. Competing risks regressions were conducted evaluate independent influence of on CVD.After PSM, CVD lower than those [decreased 53%, adjusted HR, 0.469 (95% CI, 0.255-0.862; P = 0.015)] 36%, HR model 1, 0.636 0.439-0.923; 0.017)]. The decreased age at diagnosis >60 years old [adjusted 0.390 0.200-0.760; 0.006)], diagnosed 2010 2015 0.339 0.118-0.970; 0.044)].PCNSL are associated risk. Our findings may provide new foundations for that is first-line treatment patients, according a perspective.